The power of GOULD: Amgen's LDL-C registry designed to mine PCSK9, trends in treatment
By Randy Osborne
Staff Writer
Staff Writer
Scott Wasserman, Amgen Inc.'s vice president of global development, told BioWorld Today that a new, 5,000-patient observational study will "cast a more focused light on the unmet need" in knocking down levels of LDL-C, as researchers will take "multiple snapshots" over a three-year period.
